Business Description
Compare
Compare
Traded in other countries / regions
02696.Hong Kong IPO Date
2019-09-25Description
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and innovative biologics for patients with a focus on oncology and autoimmune diseases. The company operates in Mainland China and Overseas. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.22 | |||||
| Equity-to-Asset | 0.25 | |||||
| Debt-to-Equity | 1.73 | |||||
| Debt-to-EBITDA | -6.65 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 0.26 | |||||
| Beneish M-Score | -1.9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 520.5 | |||||
| 3-Year EBITDA Growth Rate | -22 | |||||
| 3-Year EPS without NRI Growth Rate | -29.1 | |||||
| 3-Year FCF Growth Rate | -12.5 | |||||
| 3-Year Book Growth Rate | 10.9 | |||||
| Future 3-5Y Total Revenue Growth Rate | 27.67 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.8 | |||||
| 9-Day RSI | 35.47 | |||||
| 14-Day RSI | 36.13 | |||||
| 6-1 Month Momentum % | 15.89 | |||||
| 12-1 Month Momentum % | -33.17 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.49 | |||||
| Quick Ratio | 0.36 | |||||
| Cash Ratio | 0.19 | |||||
| Days Inventory | 265.8 | |||||
| Days Sales Outstanding | 55.4 | |||||
| Days Payable | 192.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.3 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 73.99 | |||||
| Operating Margin % | -15.36 | |||||
| Net Margin % | -36.42 | |||||
| ROE % | -35.04 | |||||
| ROA % | -11.42 | |||||
| ROIC % | -4.81 | |||||
| ROC (Joel Greenblatt) % | -39.1 | |||||
| ROCE % | -16.91 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.31 | |||||
| PB Ratio | 2.64 | |||||
| EV-to-EBIT | -10.98 | |||||
| EV-to-Forward-EBIT | 20.3 | |||||
| EV-to-EBITDA | -15.08 | |||||
| EV-to-Revenue | 3.42 | |||||
| EV-to-Forward-Revenue | 4.2 | |||||
| EV-to-FCF | -6.38 | |||||
| Earnings Yield (Greenblatt) % | -9.1 |
How Shanghai Henlius Biotech Inc (HKSE:02696) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Shanghai Henlius Biotech Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 2,795.741 | ||
| EPS (TTM) (HK$) | -1.898 | ||
| Beta | 0.85 | ||
| Volatility % | 42 | ||
| 14-Day RSI | 36.13 | ||
| 14-Day ATR (HK$) | 0.535993 | ||
| 20-Day SMA (HK$) | 12.979 | ||
| 12-1 Month Momentum % | -33.17 | ||
| 52-Week Range (HK$) | 10.02 - 22.9 | ||
| Shares Outstanding (Mil) | 543.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shanghai Henlius Biotech Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shanghai Henlius Biotech Inc Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Shanghai Henlius Biotech Inc Frequently Asked Questions
What is Shanghai Henlius Biotech Inc(HKSE:02696)'s stock price today?
The current price of HKSE:02696 is HK$11.70. The 52 week high of HKSE:02696 is HK$22.90 and 52 week low is HK$10.02.
When is next earnings date of Shanghai Henlius Biotech Inc(HKSE:02696)?
The next earnings date of Shanghai Henlius Biotech Inc(HKSE:02696) is .
Does Shanghai Henlius Biotech Inc(HKSE:02696) pay dividends? If so, how much?
Shanghai Henlius Biotech Inc(HKSE:02696) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
